RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence
A United States (US) payer perspective
Rothwell, B., Sheikh, K., Knight, C., Kamgar, F., Jain, R., Mamtani, R., Kurt, M., Poretta, T., Broughton, E., & Teitsson, S. (2022). Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: A United States (US) payer perspective. Value in Health, 25(7), S370. https://doi.org/10.1016/j.jval.2022.04.435